Navigation Links
Hepatitis C treatment reduces the virus but serious liver problems may progress
Date:11/6/2007

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and were reported at the annual meeting of the American Association for the Study of Liver Disease in Boston on November 5, 2007. HALT-C is funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.

"The HALT-C trial unequivocally demonstrated that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C and a program director for the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These results add to the incentive to develop more effective drugs that will benefit patients with severe liver disease due to hepatitis C."

HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, assessed whether long-term treatment with peginterferon alfa-2a reduced the development of cirrhosis, liver failure, or liver cancer. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in weekly injections for 3.5 years. The 533 patients in the control arm underwent the same follow-up and care as the treated patients including liver biopsies, quarterly clinic visits, and blood tests. All patients had advanced liver fibrosis, a gradual scarring of the liver that puts patients at risk for progressive liver disease.
'/>"/>

Contact: Leslie Curtis
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Marriagelifeinsurance.com ... find life insurance for retired couples. , Senior ... provide financial security for their loved ones. A joint ... both insured persons pass away. , Life insurance ... expense life insurance can even be purchased online, as ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... 01, 2014 T.E.N., a ... relationship-marketing firm, announced today the nominees vying ... Project of the Year Awards for North ... organizations in financial services, commercial, health care, ... endeavors that address key issues in the ...
(Date:10/1/2014)... genetic finding from Duke Medicine suggests that some people ... also be hard-wired to gain weight when exposed to ... An estimated 13 percent of people, all of whom ... this could help them reduce heart disease with simple ... management. , "Genetic susceptibility, psychosocial stress and metabolic factors ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... JACKSONVILLE, Fla., July 7 Blue Cross and Blue ... health care providers in Broward, Charlotte, Hernando, Pasco, and ... plan. This affordable option features a community-based network, allowing ... on services and premiums, without sacrificing quality coverage. ...
... LISLE, IL, July 7 /PRNewswire-FirstCall/ - SXC Health Solutions ... , TSX: SXC), a leading provider of technology and ... PBM unit has been awarded an 18-month contract, with ... services to Presbyterian Health Plan, a health maintenance organization ...
... Drug Study Dosages to Address Bone Density, Heart Health and Joint ... Inc. (Nasdaq: NXXI ), a developer and marketer of ... health, enhance memory and address chronic joint pain today announced the ... PRESCRIPTIX (TM). , , The ...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... candidate from two series of purine analogs for the ... is a proprietary nucleotide analog polymerase inhibitor of HCV ... of an Investigational New Drug (IND) application with the ...
... Blood Education , , BROOKEVILLE, Md., July 7 Expectant ... study published in the Journal of ... e . In fact, of the expectant mothers in the ... 74 percent considered themselves minimally informed. Yet, the Institute of ...
... simple, effective alternative to tubal ligation , , ... the Company) (Nasdaq: HOLX ), a leading ... systems and surgical products dedicated to serving the healthcare ... Drug Administration (FDA) has approved the Company,s premarket approval ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Florida Expands Low-Cost 'BlueSelect' Health Plan to Five Florida Counties 2Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 2Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 3Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 4Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 2Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 3Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 4Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 5Health News:Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 2Health News:Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 3Health News:Parent's Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 2Health News:Parent's Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 3Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 2Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 3Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 4Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 5
(Date:10/1/2014)... BOSTON and NOTTINGHAM, England ... CBRX ) today announced that its subsidiary, ... to Clinical Trials platform at the annual CPhI/ICSE Worldwide ... which aims to support companies with the rapid development ... The new enabling technologies screening platform, which incorporates the ...
(Date:10/1/2014)... and NEW YORK , October 1, 2014 ... Organization (CRO) and service provider for the medical industries, announced today ... offices in New York City . genae Americas ... is strategically centered in one of the highest concentrations ... said Philippe Kassab , President at genae Americas. "The expansion ...
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... CHICAGO, Nov. 16, 2010 New results from ... at the American Heart Association (AHA) Scientific Sessions ... (prasugrel) prior to coronary artery bypass graft surgery ... to patients treated with Plavix® (clopidogrel) (2.3 percent ...
... RIDGE, N.J., Nov. 16, 2010 Regado Biosciences, Inc., ... aptamers with active control agents, announced that Thomas J. ... abstract at the AHA Scientific Sessions meeting on November ... The abstract, entitled "RB006, a Direct Factor ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 2Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 3Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 4
... fully automated genetic analysis system. This system ... patented linear polyacrylamide (LPA) gel, denatures and ... and analyzes the data. Software tools let ... customize automated data assessment. All to ensure ...
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
... Sorvall Discovery 90SE Ultracentrifuge ... to discover more. All ... with top-of-the-line performance, powerful ... of use, all built ...
Medicine Products: